Beneficial of adding Tocilizumab to standard care in critical forms of Covid-19 pneumonia: Study on paired series

Introduction: Tocilizumab (TCZ), a humanized monoclonal antibody directed against interleukin-6 (IL-6) receptors, has been tried in various studies as a Covid-19 therapy with controversial results. Aim: To evaluate the effectiveness of adding TCZ to standard care (SC) in critical Covid-19 patients....

Full description

Saved in:
Bibliographic Details
Published inTunisie Medicale Vol. 100; no. 4; pp. 309 - 312
Main Authors Trif, Ahlem, Abdennebi, Cyrine, Mehdi, Asma, Ben Romdhane, Kais, Blel, Youssef, Daly, Foued, Zakhama, Boubaker, Mestiri, Taher, Abdellatif, Sami, Ben Lakhal, Salah
Format Journal Article
LanguageEnglish
Published Tunisian Society of Medical Sciences 01.04.2022
Online AccessGet full text

Cover

Loading…
Abstract Introduction: Tocilizumab (TCZ), a humanized monoclonal antibody directed against interleukin-6 (IL-6) receptors, has been tried in various studies as a Covid-19 therapy with controversial results. Aim: To evaluate the effectiveness of adding TCZ to standard care (SC) in critical Covid-19 patients. Methods: it was designed retrospectively as a comparative study on two paired series of critical patients affected with Covid-19: the 1 st group received TCZ plus SC versus a 2 nd group which received only SC. The matching criteria were age, sex and severity score and the matching was based on the propensity score matching (PSM) by the nearest neighbor. Outcomes were: survival, mechanical ventilation (MV) and nosocomial infections. Results: Ninety patients were included by pairing estimated successful (PSM > 0.5 in more than 50% in each group for all matching criteria). 55.5% of SC group progressed to stage 3-acute respiratory distress syndrome (ARDS) versus 31% of TCZ+SC patients (p=0.03). No effect of TCZ was found on mortality (49% in each group, p=1) nor on MV use (p=0.67). ICU stay was more prolonged in TCZ+SC group (16 versus 8 days, p <10 -3 ). The administration of TCZ induced a significant decrease in CRP but not changed the IL-6 dosage. Nosocomial infections occurred in 18 (40%) of TCZ+SC group comparatively to 15 (33,5%) of SC group, p=0.66. Conclusion: Tocilizumab reduced the risk of progression to severe ARDS probably due to its immune-modulating properties. But no beneficial effect was found on survival or on the use of ventilation.
AbstractList Introduction: Tocilizumab (TCZ), a humanized monoclonal antibody directed against interleukin-6 (IL-6) receptors, has been tried in various studies as a Covid-19 therapy with controversial results. Aim: To evaluate the effectiveness of adding TCZ to standard care (SC) in critical Covid-19 patients. Methods: it was designed retrospectively as a comparative study on two paired series of critical patients affected with Covid-19: the 1 st group received TCZ plus SC versus a 2 nd group which received only SC. The matching criteria were age, sex and severity score and the matching was based on the propensity score matching (PSM) by the nearest neighbor. Outcomes were: survival, mechanical ventilation (MV) and nosocomial infections. Results: Ninety patients were included by pairing estimated successful (PSM > 0.5 in more than 50% in each group for all matching criteria). 55.5% of SC group progressed to stage 3-acute respiratory distress syndrome (ARDS) versus 31% of TCZ+SC patients (p=0.03). No effect of TCZ was found on mortality (49% in each group, p=1) nor on MV use (p=0.67). ICU stay was more prolonged in TCZ+SC group (16 versus 8 days, p <10 -3 ). The administration of TCZ induced a significant decrease in CRP but not changed the IL-6 dosage. Nosocomial infections occurred in 18 (40%) of TCZ+SC group comparatively to 15 (33,5%) of SC group, p=0.66. Conclusion: Tocilizumab reduced the risk of progression to severe ARDS probably due to its immune-modulating properties. But no beneficial effect was found on survival or on the use of ventilation.
Author Daly, Foued
Zakhama, Boubaker
Trif, Ahlem
Mehdi, Asma
Abdennebi, Cyrine
Abdellatif, Sami
Ben Romdhane, Kais
Blel, Youssef
Mestiri, Taher
Ben Lakhal, Salah
Author_xml – sequence: 1
  givenname: Ahlem
  surname: Trif
  fullname: Trif, Ahlem
  organization: 1. Medical ICU, teaching hospital la Rabta, 4. University Tunis El Manar Tunis, Tunisie
– sequence: 2
  givenname: Cyrine
  surname: Abdennebi
  fullname: Abdennebi, Cyrine
  organization: 1. Medical ICU, teaching hospital la Rabta, 4. University Tunis El Manar Tunis, Tunisie
– sequence: 3
  givenname: Asma
  surname: Mehdi
  fullname: Mehdi, Asma
  organization: 1. Medical ICU, teaching hospital la Rabta, 4. University Tunis El Manar Tunis, Tunisie
– sequence: 4
  givenname: Kais
  surname: Ben Romdhane
  fullname: Ben Romdhane, Kais
  organization: 4. University Tunis El Manar Tunis, Tunisie 2. Medical ICU, Carthagène polyclinic
– sequence: 5
  givenname: Youssef
  surname: Blel
  fullname: Blel, Youssef
  organization: 4. University Tunis El Manar Tunis, Tunisie 2. Medical ICU, Carthagène polyclinic
– sequence: 6
  givenname: Foued
  surname: Daly
  fullname: Daly, Foued
  organization: 1. Medical ICU, teaching hospital la Rabta, 4. University Tunis El Manar Tunis, Tunisie
– sequence: 7
  givenname: Boubaker
  surname: Zakhama
  fullname: Zakhama, Boubaker
  organization: 4. University Tunis El Manar Tunis, Tunisie 2. Medical ICU, Carthagène polyclinic
– sequence: 8
  givenname: Taher
  surname: Mestiri
  fullname: Mestiri, Taher
  organization: 4. University Tunis El Manar Tunis, Tunisie 3. Special hospital for Covid-19 patients, El-Menzah sports city
– sequence: 9
  givenname: Sami
  surname: Abdellatif
  fullname: Abdellatif, Sami
  organization: 1. Medical ICU, teaching hospital la Rabta, 4. University Tunis El Manar Tunis, Tunisie
– sequence: 10
  givenname: Salah
  surname: Ben Lakhal
  fullname: Ben Lakhal, Salah
  organization: 1. Medical ICU, teaching hospital la Rabta, 4. University Tunis El Manar Tunis, Tunisie
BookMark eNpVjM1KxDAURoMoOI7zDvcFCknTmTQuBB38gwEXzr6kyc14pU1q0g6MT29FN36bszic74qdhxjwjC1KVVaF4lKcswXnlSgqIcUlW-X8wedtuNBrsWCf9xjQkyXTQfRgnKNwgH201NHX1JsWxgh5NMGZ5MCahEABbKKR7Jz4mPr8E27jkVwhNAwBpz4GMjfwNk7uBDHAYCihg4yJMF-zC2-6jKs_Ltn-8WG_fS52r08v27tdMYhyPRZacO18bWreitpXeuOdVkprhV6jb6XlTrqSS97ydu117SzWOGsvsJYbL5fs9vd2mNoeZxvGZLpmSNSbdGqioea_CfTeHOKx0ZVSolLyG7DdZYc
ContentType Journal Article
Copyright 2022
Copyright_xml – notice: 2022
DBID 5PM
DatabaseName PubMed Central (Full Participant titles)
DatabaseTitleList
DeliveryMethod fulltext_linktorsrc
EISSN 2724-7031
EndPage 312
GroupedDBID 5PM
ALMA_UNASSIGNED_HOLDINGS
F5P
OK1
PGMZT
RPM
ID FETCH-LOGICAL-p125t-9109df8a80b18f496fd977997ef9efb3c0d3d2030b0b5f98dce8e997f1e836f3
IEDL.DBID RPM
ISSN 0041-4131
IngestDate Tue Sep 17 21:36:15 EDT 2024
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p125t-9109df8a80b18f496fd977997ef9efb3c0d3d2030b0b5f98dce8e997f1e836f3
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477147/
PageCount 4
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9477147
PublicationCentury 2000
PublicationDate 20220401
PublicationDateYYYYMMDD 2022-04-01
PublicationDate_xml – month: 4
  year: 2022
  text: 20220401
  day: 1
PublicationDecade 2020
PublicationTitle Tunisie Medicale
PublicationYear 2022
Publisher Tunisian Society of Medical Sciences
Publisher_xml – name: Tunisian Society of Medical Sciences
SSID ssj0000601951
Score 2.2646155
Snippet Introduction: Tocilizumab (TCZ), a humanized monoclonal antibody directed against interleukin-6 (IL-6) receptors, has been tried in various studies as a...
SourceID pubmedcentral
SourceType Open Access Repository
StartPage 309
Title Beneficial of adding Tocilizumab to standard care in critical forms of Covid-19 pneumonia: Study on paired series
URI https://pubmed.ncbi.nlm.nih.gov/PMC9477147
Volume 100
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV09T8MwELVKJxYEAsS3bmBNmw8njtmgoqqQihiK1K3yJ0RqnUDTAX495ySV2pXZsqz4nOf3rHd3hNxbI7LQGh1QTXlArYwCKREMNUPVE0skHM17x_Q1m7zTl3k675F0mwvTmPaVLAZuuRq44rPxVlYrNdz6xIZv0xGnjEWUDQ_IAUuSHYnewq_PgWs75VHUR5HvH7dveNy5QcbH5KijfvDYLnFCesadkq8nBJu2igOUFry9x33ADLdsWfxuVkJCXcJW74P3aUHhQHUNCsBTzrWfOPIJdUHEoXJmg0erEA_gPYI_UDqoBAKbBn_azPqMzMbPs9Ek6NogBBWyjxrhKOTa5iIPZZRbyjOrkbRxzozlxspEhTrRMf6sMpSp5Tl-ZW5w2EYmTzKbnJO-K525ICBQG3CZy8gkggphhcqEZtwomdk0VuElYXv7tKjaihcLX4N6fwRD09Si7kJx9e-Z1-Qw9hkFjRnmhvTr7425xXu-lndNXP8AhquxRQ
link.rule.ids 230,315,733,786,790,891,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELZKGWDhIUC88cCaNg_nYTaoqAq0FUNB3So7tiGidQJNBvrrOSeN1LLBfLIcnS-fv7O-u0PoWkkW2EoKiwhCLaK4Y3EOYChCyHpcDoSjfO8YDIPeC3kc--MG8utamFK0H_Okpaezlk7eS21lNovbtU6s_TzoUBKGDgnbG2gT_lfXX0nSKwA2VXDVrDwCGZJjJsitSx5X7pDuLnqtd6-kIx-tIuetePGrMeOfP28P7SxZJb6tzPuoIfUB-rwDHKsaROBUYaMc0m94BKcxTRbFjHGcp7h-SsBGAoYTjePl7ANs2OzcLOyYWj3LoTjTsoCoTdgNNvLDb5xqnDHATIFNIMv5IRp170ednrWcsGBlQGxyQDqbChWxyOZOpAgNlAA-SGkoFZWKe7EtPOECDnCb-4pG4L5Iglk5MvIC5R2hpk61PEaYQdpBecQd6THCmGJxwERIZcwD5buxfYLCtQOYZFUzjYlpb71uAbeWba6Xbjz998ortNUbDfqT_sPw6Qxtu6ZwodTcnKNm_lXIC6ATOb8sg-cHNtvTQg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELagSIiFhwDxxgNr3m4Ss0GhKo9WHYpUsVR2bENE6wSaDPTXc05aqWXsbFuyzufP31nf3SF0oyQLXSWFRQShFlHcszgHMBQRRD0-B8JR_Xd0e2HnjTwPm8OlVl-VaD_hqa3HE1unn5W2Mp8kzkIn5vS7LUqiyCORkwvlbKItuLN-tBSo1yBsMuHqfnkEoiTPdJFblT0uvSPtPfS-2EEtH_myy4Lbyexfcca1triPdufsEt_VUw7QhtSH6Pse8KwuFIEzhY2CSH_gAZzKOJ2VE8ZxkeHFlwI2UjCcapzMeyBgw2qnZmHL5OxZHsW5liV4b8pusZEh_uJM45wBdgpsHFpOj9Cg_Thodax5pwUrB4JTAOK5VKiYxS73YkVoqATwQkojqahUPEhcEQgf8IC7vKloDCaMJQwrT8ZBqIJj1NCZlicIMwg_KI-5JwNGGFMsCZmIqEx4qJp-4p6iaOUQRnldVGNkylyvjoBpq3LXc1Oerb3yGm33H9qj16feyzna8U3-QiW9uUCN4qeUl8AqCn5V-c8fvp_Vwg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Beneficial+of+adding+Tocilizumab+to+standard+care+in+critical+forms+of+Covid-19+pneumonia%3A+Study+on+paired+series&rft.jtitle=Tunisie+Medicale&rft.au=Trif%2C+Ahlem&rft.au=Abdennebi%2C+Cyrine&rft.au=Mehdi%2C+Asma&rft.au=Ben+Romdhane%2C+Kais&rft.date=2022-04-01&rft.pub=Tunisian+Society+of+Medical+Sciences&rft.issn=0041-4131&rft.eissn=2724-7031&rft.volume=100&rft.issue=4&rft.spage=309&rft.epage=312&rft.externalDBID=PMC9477147
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-4131&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-4131&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-4131&client=summon